Drug Trial Radar · NCT07024797
Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants
Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Aug 21, 2025
Primary completion
Dec 8, 2025
Study completion Dec 8, 2025
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jun 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will assess the adverse events, tolerability, and how oral doses of ABBV-932 moves through the body in healthy adult Chinese participants.
Conditions
- Healthy Volunteer
Interventions
ABBV-932Drug
Oral Capsule
Placebo for ABBV-932Drug
Oral Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Plasma Concentration (Cmax) of ABBV-932Time frame: Up to approximately 43 days
- Time to Cmax (Tmax) of ABBV-932Time frame: Up to approximately 43 days
- Observed plasma concentration at the end of a dosing interval (Ctrough) of ABBV-932Time frame: Up to approximately 43 days
- Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of Desmethyl Cariprazine ABBV-932Time frame: Up to approximately 43 days
- Maximum Plasma Concentration (Cmax) of DCARTime frame: Up to approximately 43 days
- Time to Cmax (Tmax) of DCARTime frame: Up to approximately 43 days
- Observed plasma concentration at the end of a dosing interval (Ctrough) of DCARTime frame: Up to approximately 43 days
- Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of Desmethyl Cariprazine (DCAR)Time frame: Up to approximately 43 days
- Maximum Plasma Concentration (Cmax) of Didesmethyl-Cariprazine (DDCAR)Time frame: Up to approximately 43 days
- Time to Cmax (Tmax) of DDCARTime frame: Up to approximately 43 days
- Observed plasma concentration at the end of a dosing interval (Ctrough) of DDCARTime frame: Up to approximately 43 days
- Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of DDCARTime frame: Up to approximately 43 days
- Number of Participants Experiencing Adverse EventsTime frame: Up to approximately 75 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Mental Health Center /ID# 273427
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.